{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:16:47Z","timestamp":1793945807569,"version":"4.8.0"},"reference-count":96,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012154","name":"Graduate Research and Innovation Projects of Jiangsu Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012154","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Proteolysis Targeting Chimera (PROTAC) is a heterobifunctional molecule comprising three core components: a target protein ligand (typically a small-molecule inhibitor), a linker, and an E3 ubiquitin ligase ligand. By harnessing the specificity of the endogenous ubiquitin-proteasome system (UPS), PROTACs induce ubiquitination and subsequent degradation of target proteins. This technology constitutes an advanced therapeutic strategy for selective protein degradation, thereby expanding the horizons of drug design. Its significant therapeutic potential extends to treating cancers, viral infections (e.g., HIV and SARS-CoV-2), and chronic diseases. Recent clinical studies on compounds such as ARV-471 have yielded encouraging results, validating the efficacy of this approach. Over the past decade, PROTAC technology has garnered widespread attention in biomedicine for its promise in developing novel targeted therapies. This review will elucidate the broad therapeutic prospects and future challenges of PROTACs by detailing their mechanism of action, recent advances, progress in targeted therapy research, and current clinical trial landscape.<\/jats:p>","DOI":"10.3389\/fonc.2025.1676414","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:19:20Z","timestamp":1761542360000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["PROTAC: a revolutionary technology propelling small molecule drugs into the next golden age"],"prefix":"10.3389","volume":"15","author":[{"given":"Jiale","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqiu","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qunshan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nrm1552","article-title":"Proteolysis: from the lysosome to ubiquitin and the proteasome","volume":"6","author":"Ciechanover","year":"2005","journal-title":"Nat Rev Mol Cell Biol Jan"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(20)82050-X","article-title":"Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown","volume":"258","author":"Hershko","year":"1983","journal-title":"J Biol Chem"},{"key":"B3","article-title":"UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme","volume":"63","author":"Okamoto","year":"2003","journal-title":"Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222312858","article-title":"Development of a PROTAC-based targeting strategy provides a mechanistically unique mode of anti-cytomegalovirus activity","volume":"22","author":"Hahn","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-019-0144-9","article-title":"Degrading proteins in animals: \"PROTAC\"tion goes in vivo","volume":"29","author":"Guo","year":"2019","journal-title":"Cell Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/biom12091257","article-title":"Recent advances of degradation technologies based on PROTAC mechanism","volume":"12","author":"Xiao","year":"2022","journal-title":"Biomolecules"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2017.02.027","article-title":"Targeted protein degradation by PROTACs","volume":"174","author":"Neklesa","year":"2017","journal-title":"Pharmacol Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1039\/d2cs00193d","article-title":"PROTACs: past, present and future","volume":"51","author":"Li","year":"2022","journal-title":"Chem Soc Rev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2020.02.006","article-title":"PROTACs: A novel strategy for cancer therapy","volume":"67","author":"Liu","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2019.110452","article-title":"Targeting nuclear receptors with PROTAC degraders","volume":"493","author":"Flanagan","year":"2019","journal-title":"Mol Cell Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3779\/j.issn.1009-3419.2022.102.19","article-title":"Research progress of proteolysis targeting chimeria in NSCLC therapy","volume":"25","author":"Jiang","year":"2022","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1021\/ja039025z","article-title":"Chemical genetic control of protein levels: selective in vivo targeted degradation","volume":"126","author":"Schneekloth","year":"2004","journal-title":"J Am Chem Soc"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.320","article-title":"Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer","volume":"27","author":"Rodriguez-Gonzalez","year":"2008","journal-title":"Oncogene"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.200700438","article-title":"Targeted degradation of the aryl hydrocarbon receptor by the PROTAC approach: a useful chemical genetic tool","volume":"8","author":"Lee","year":"2007","journal-title":"Chembiochem"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.T300009-MCP200","article-title":"Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation","volume":"2","author":"Sakamoto","year":"2003","journal-title":"Mol Cell Proteomics"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2008.07.114","article-title":"Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics","volume":"18","author":"Schneekloth","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1021\/ja209924v","article-title":"Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL\/HIF-1\u03b1 interaction","volume":"134","author":"Buckley","year":"2012","journal-title":"J Am Chem Soc"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nrg.2016.13","article-title":"Epigenetic modulators, modifiers and mediators in cancer aetiology and progression","volume":"17","author":"Feinberg","year":"2016","journal-title":"Nat Rev Genet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00365-x","article-title":"Advancing targeted protein degradation for cancer therapy","volume":"21","author":"Dale","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202217246","article-title":"Discovery of norbornene as a novel hydrophobic tag applied in protein degradation","volume":"62","author":"Xie","year":"2023","journal-title":"Angew Chem Int Ed Engl"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c01659","article-title":"Solid-phase synthesis of cereblon-recruiting selective histone deacetylase 6 degraders (HDAC6 PROTACs) with antileukemic activity","volume":"65","author":"Sinatra","year":"2022","journal-title":"J Med Chem"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.7150\/thno.92526","article-title":"Degraders in epigenetic therapy: PROTACs and beyond","volume":"14","author":"Dai","year":"2024","journal-title":"Theranostics"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.7150\/thno.73223","article-title":"Histone acetyltransferases CBP\/p300 in tumorigenesis and CBP\/p300 inhibitors as promising novel anticancer agents","volume":"12","author":"Chen","year":"2022","journal-title":"Theranostics"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3256","article-title":"BET domain co-regulators in obesity, inflammation and cancer","volume":"12","author":"Belkina","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.12.013","article-title":"Transcriptional addiction in cancer","volume":"168","author":"Bradner","year":"2017","journal-title":"Cell"},{"key":"B30","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/s41419-019-2022-2","article-title":"PROTAC induced-BET protein degradation exhibits potent anti-osteosarcoma activity by triggering apoptosis","volume":"10","author":"Shi","year":"2019","journal-title":"Cell Death Dis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1600-065X.2008.00741.x","article-title":"Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain","volume":"228","author":"Mohamed","year":"2009","journal-title":"Immunol Rev"},{"key":"B32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1053\/j.seminhematol.2015.01.008","article-title":"B-cell receptor signaling in diffuse large B-cell lymphoma","volume":"52","author":"Young","year":"2015","journal-title":"Semin Hematol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.chembiol.2017.10.005","article-title":"A chemoproteomic approach to query the degradable kinome using a multi-kinase degrader","volume":"25","author":"Huang","year":"2018","journal-title":"Cell Chem Biol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.0c00411","article-title":"Targeted degradation of oncogenic KRAS(G12C) by VHL-recruiting PROTACs","volume":"6","author":"Bond","year":"2020","journal-title":"ACS Cent Sci"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1538-7445.AM2023-5735","article-title":"Abstract 5735: Novel KRAS G12D degrader ASP3082 demonstrates in vivo, dose-dependent KRAS degradation, KRAS pathway inhibition, and antitumor efficacy in multiple KRAS G12D-mutated cancer models","volume":"83","author":"Nagashima","year":"2023","journal-title":"Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02635-7","article-title":"IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial","volume":"29","author":"Ackerman","year":"2023","journal-title":"Nat Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA118.003314","article-title":"Interleukin-1 receptor-associated kinase 4 (IRAK4) plays a dual role in myddosome formation and Toll-like receptor signaling","volume":"293","author":"De Nardo","year":"2018","journal-title":"J Biol Chem"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-023-00883-2","article-title":"Tau-targeting therapies for Alzheimer disease: current status and future directions","volume":"19","author":"Congdon","year":"2023","journal-title":"Nat Rev Neurol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.7150\/thno.55680","article-title":"A novel small-molecule PROTAC selectively promotes tau clearance to improve cognitive functions in Alzheimer-like models","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2016.02.016","article-title":"Specific knockdown of endogenous tau protein by peptide-directed ubiquitin-proteasome degradation","volume":"23","author":"Chu","year":"2016","journal-title":"Cell Chem Biol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1920251117","article-title":"bioPROTACs as versatile modulators of intracellular therapeutic targets including proliferating cell nuclear antigen (PCNA)","volume":"117","author":"Lim","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.2c11706","article-title":"Targeted dephosphorylation of tau by phosphorylation targeting chimeras (PhosTACs) as a therapeutic modality","author":"Hu","year":"2023","journal-title":"J Am Chem Soc"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aay5064","article-title":"PHOTACs enable optical control of protein degradation","volume":"6","author":"Reynders","year":"2020","journal-title":"Sci Adv"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.9b00713","article-title":"Reversible spatiotemporal control of induced protein degradation by bistable photoPROTACs","volume":"5","author":"Pfaff","year":"2019","journal-title":"ACS Cent Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2020.08.003","article-title":"PhotoPROTACs: A novel biotechnology for cancer treatment","volume":"30","author":"Wang","year":"2020","journal-title":"Trends Cell Biol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1038\/s41467-021-23194-w","article-title":"Semiconducting polymer nano-PROTACs for activatable photo-immunometabolic cancer therapy","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat Commun"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1021\/cr300177k","article-title":"Photoremovable protecting groups in chemistry and biology: reaction mechanisms and efficacy","volume":"113","author":"Kl\u00e1n","year":"2013","journal-title":"Chem Rev"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.1c03852","article-title":"TF-PROTACs enable targeted degradation of transcription factors","volume":"143","author":"Liu","year":"2021","journal-title":"J Am Chem Soc"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.0c00285","article-title":"Antibody-PROTAC conjugates enable HER2-dependent targeted protein degradation of BRD4","volume":"15","author":"Maneiro","year":"2020","journal-title":"ACS Chem Biol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.1c00576","article-title":"RIBOTACs: small molecules selectively destroy cancer-associated RNA","volume":"12","author":"Kargbo","year":"2021","journal-title":"ACS Med Chem Lett"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202503958","article-title":"Nanoparticle-mediated targeted protein degradation: an emerging therapeutics technology","volume":"64","author":"Baker","year":"2025","journal-title":"Angew Chem Int Ed Engl"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/s41565-021-00996-z","article-title":"Size-dependent nano-bio interactions","volume":"16","author":"Pastore","year":"2021","journal-title":"Nat Nanotechnol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.4c11556","article-title":"Leveraging dual-ligase recruitment to enhance protein degradation via a heterotrivalent proteolysis targeting chimera","volume":"146","author":"Bond","year":"2024","journal-title":"J Am Chem Soc"},{"key":"B54","doi-asserted-by":"publisher","first-page":"6509","DOI":"10.1038\/s41467-023-42233-2","article-title":"Expanding PROTACtable genome universe of E3 ligases","volume":"14","author":"Liu","year":"2023","journal-title":"Nat Commun"},{"key":"B55","doi-asserted-by":"publisher","first-page":"99","DOI":"10.15212\/amm-2024-0075","article-title":"PROTAC technology for prostate cancer treatment","volume":"4","author":"Wang","year":"2025","journal-title":"Acta Mater Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.108000","article-title":"Proteomic study identifies Aurora-A-mediated regulation of alternative splicing through multiple splicing factors","volume":"301","author":"Damodaran","year":"2025","journal-title":"J Biol Chem"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2023.117259","article-title":"CRBN ligand expansion for hematopoietic prostaglandin D(2) synthase (H-PGDS) targeting PROTAC design and their in vitro ADME profiles","volume":"84","author":"Osawa","year":"2023","journal-title":"Bioorg Med Chem"},{"key":"B58","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s42004-025-01598-9","article-title":"Synthesis, biological evaluation and clinical trials of Cereblon-based PROTACs","volume":"8","author":"Vicente","year":"2025","journal-title":"Commun Chem"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1039\/d2cs00624c","article-title":"Emerging degrader technologies engaging lysosomal pathways","volume":"51","author":"Ding","year":"2022","journal-title":"Chem Soc Rev"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biochem.2c00310","article-title":"Targeted protein degradation via lysosomes","volume":"62","author":"Paudel","year":"2023","journal-title":"Biochemistry"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15102442","article-title":"TACkling cancer by targeting selective protein degradation","volume":"15","author":"Noblejas-L\u00f3pez","year":"2023","journal-title":"Pharmaceutics"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109574","article-title":"Inhibitors to degraders: Changing paradigm in drug discovery","volume":"27","author":"Haridas","year":"2024","journal-title":"iScience"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2023.2187777","article-title":"Novel approaches to targeted protein degradation technologies in drug discovery","volume":"18","author":"Xue","year":"2023","journal-title":"Expert Opin Drug Discov"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biochem.1c00330","article-title":"Redefining the scope of targeted protein degradation: translational opportunities in hijacking the autophagy-lysosome pathway","volume":"62","author":"Cassidy","year":"2023","journal-title":"Biochemistry"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26125582","article-title":"Emerging concepts of targeted protein degrader technologies via lysosomal pathways","volume":"26","author":"Alam","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B66","volume-title":"A phase 1\/2, Open-label, Dose Escalation, and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer","year":""},{"key":"B67","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s43556-022-00112-0","article-title":"An overview of PROTACs: a promising drug discovery paradigm","volume":"3","author":"Liu","year":"2022","journal-title":"Mol Biomed"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27061977","article-title":"Development of an LC-MS\/MS method for ARV-110, a PROTAC molecule, and applications to pharmacokinetic studies","volume":"27","author":"Nguyen","year":"2022","journal-title":"Molecules"},{"key":"B69","volume-title":"A Phase 1\/2, Open Label, Dose Escalation, and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-471 Alone and in Combination With Palbociclib (IBRANCE\u00ae) in Patients With Estrogen Receptor Positive\/Human Epidermal Growth Factor Receptor 2 Negative (ER+\/HER2-) Locally Advanced or Metastatic Breast Cancer, Who Have Received Prior Hormonal Therapy and Chemotherapy in the Locally Advanced\/Metastatic Setting","year":""},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.692574","article-title":"PROTAC: An effective targeted protein degradation strategy for cancer therapy","volume":"12","author":"Qi","year":"2021","journal-title":"Front Pharmacol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2020.07.013","article-title":"Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective","volume":"25","author":"Pike","year":"2020","journal-title":"Drug Discov Today"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.crchbi.2022.100029","article-title":"Discovery of a potent BTK and IKZF1\/3 triple degrader through reversible covalent BTK PROTAC development","author":"Yu","year":"2022","journal-title":"Curr Res Chem Biol"},{"key":"B73","volume-title":"A phase 1, Dose Escalation, Safety and Tolerability Study of NX-2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed\/Refractory B-cell Malignancies","year":""},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016934","article-title":"NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts","volume":"141","author":"Zhang","year":"2023","journal-title":"Blood"},{"key":"B75","volume-title":"A Phase 1 Randomized, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)","year":""},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3390\/molecules30102123","article-title":"PROTAC technology as a new tool for modern pharmacotherapy","volume":"30","author":"Kubry\u0144","year":"2025","journal-title":"Molecules"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202314132","article-title":"PROTAC prodrug-integrated nanosensitizer for potentiating radiation therapy of cancer","volume":"36","author":"Zhang","year":"2024","journal-title":"Adv Mater"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2025.e00548","article-title":"Proteolytic therapeutic modalities for amyloidoses: Insights into immunotherapy, PROTAC, and photo-oxygenation","volume":"22","author":"Kuriyama","year":"2025","journal-title":"Neurotherapeutics"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.3c02783","article-title":"Telomere targeting chimera enables targeted destruction of telomeric repeat-binding factor proteins","volume":"145","author":"Wang","year":"2023","journal-title":"J Am Chem Soc"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c00026","article-title":"Rational design and optimization of a potent IDO1 proteolysis targeting chimera (PROTAC)","volume":"68","author":"Monsen","year":"2025","journal-title":"J Med Chem"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1016\/j.chembiol.2022.08.004","article-title":"Target protein localization and its impact on PROTAC-mediated degradation","volume":"29","author":"Simpson","year":"2022","journal-title":"Cell Chem Biol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.4c00500","article-title":"Clozapine as an E3 ligand for PROTAC technology","volume":"16","author":"Takano","year":"2025","journal-title":"ACS Med Chem Lett"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28104014","article-title":"PROTACs: emerging targeted protein degradation approaches for advanced druggable strategies","volume":"28","author":"Sincere","year":"2023","journal-title":"Molecules"},{"key":"B84","article-title":"Investigation of incidence and risk factors of subcutaneous granulomas induced by injection of leuprorelin acetate","volume":"61","author":"Fukui","year":"2015","journal-title":"Hinyokika Kiyo"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112769","article-title":"Design and characterization of cereblon-mediated androgen receptor proteolysis-targeting chimeras","volume":"208","author":"Takwale","year":"2020","journal-title":"Eur J Med Chem"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112903","article-title":"First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2\/4\/6 in vivo","volume":"209","author":"Wei","year":"2021","journal-title":"Eur J Med Chem"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.202100270","article-title":"Recent developments in PROTAC-mediated protein degradation: from bench to clinic","volume":"23","author":"Hu","year":"2022","journal-title":"Chembiochem"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-021-00770-1","article-title":"LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation","volume":"17","author":"Ahn","year":"2021","journal-title":"Nat Chem Biol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.molcel.2019.09.009","article-title":"AUTACs: cargo-specific degraders using selective autophagy","volume":"76","author":"Takahashi","year":"2019","journal-title":"Mol Cell"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.4155\/fmc-2021-0223","article-title":"Challenges and opportunities for in vivo PROTAC delivery","volume":"14","author":"Benowitz","year":"2022","journal-title":"Future Med Chem"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/s41421-018-0079-1","article-title":"A chemical approach for global protein knockdown from mice to non-human primates","volume":"5","author":"Sun","year":"2019","journal-title":"Cell Discov"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2019.1659242","article-title":"PROTACs- a game-changing technology","volume":"14","author":"Konstantinidou","year":"2019","journal-title":"Expert Opin Drug Discov"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0047-y","article-title":"Targeted protein degradation: expanding the toolbox","volume":"18","author":"Schapira","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.9b00704","article-title":"Development of small molecule chimeras that recruit ahR E3 ligase to target proteins","volume":"14","author":"Ohoka","year":"2019","journal-title":"ACS Chem Biol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.2329","article-title":"Structural basis of PROTAC cooperative recognition for selective protein degradation","volume":"13","author":"Gadd","year":"2017","journal-title":"Nat Chem Biol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17040501","article-title":"PROTAC delivery strategies for overcoming physicochemical properties and physiological barriers in targeted protein degradation","volume":"17","author":"Syahputra","year":"2025","journal-title":"Pharmaceutics"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1676414\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:19:25Z","timestamp":1761542365000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1676414\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":96,"alternative-id":["10.3389\/fonc.2025.1676414"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1676414","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"article-number":"1676414"}}